These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18761414)

  • 1. Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates.
    Guimond A; Viau E; Aubé P; Renzi PM; Paquet L; Ferrari N
    Pulm Pharmacol Ther; 2008 Dec; 21(6):845-54. PubMed ID: 18761414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response effects of TPI ASM8 in asthmatics after allergen.
    Gauvreau GM; Pageau R; Séguin R; Carballo D; Gauthier J; D'Anjou H; Campbell H; Watson R; Mistry M; Parry-Billings M; Killian K; Renzi PM
    Allergy; 2011 Sep; 66(9):1242-8. PubMed ID: 21605124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses.
    Gauvreau GM; Boulet LP; Cockcroft DW; Baatjes A; Cote J; Deschesnes F; Davis B; Strinich T; Howie K; Duong M; Watson RM; Renzi PM; O'Byrne PM
    Am J Respir Crit Care Med; 2008 May; 177(9):952-8. PubMed ID: 18244953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge.
    Imaoka H; Campbell H; Babirad I; Watson RM; Mistry M; Sehmi R; Gauvreau GM
    Clin Exp Allergy; 2011 Dec; 41(12):1740-6. PubMed ID: 21762225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys.
    Burel SA; Han SR; Lee HS; Norris DA; Lee BS; Machemer T; Park SY; Zhou T; He G; Kim Y; MacLeod AR; Monia BP; Lio S; Kim TW; Henry SP
    Nucleic Acid Ther; 2013 Jun; 23(3):213-27. PubMed ID: 23692080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local and systemic tolerability of a 2'O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey.
    Fey RA; Templin MV; McDonald JD; Yu RZ; Hutt JA; Gigliotti AP; Henry SP; Reed MD
    Inhal Toxicol; 2014 Jul; 26(8):452-63. PubMed ID: 24932560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
    Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
    Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of SPECT-CT Imaging to Study the Pharmacokinetics of Antisense Oligonucleotides in a Mouse Model of Duchenne Muscular Dystrophy.
    van de Steeg E; Läppchen T; Aguilera B; Jansen HT; Muilwijk D; Vermue R; van der Hoorn JW; Donato K; Rossin R; de Visser PC; Vlaming MLH
    Nucleic Acid Ther; 2017 Aug; 27(4):221-231. PubMed ID: 28418733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
    Geary RS; Yu RZ; Watanabe T; Henry SP; Hardee GE; Chappell A; Matson J; Sasmor H; Cummins L; Levin AA
    Drug Metab Dispos; 2003 Nov; 31(11):1419-28. PubMed ID: 14570775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys.
    Webb MS; Tortora N; Cremese M; Kozlowska H; Blaquiere M; Devine DV; Kornbrust DJ
    Antisense Nucleic Acid Drug Dev; 2001 Jun; 11(3):155-63. PubMed ID: 11446591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys.
    Yu RZ; Geary RS; Monteith DK; Matson J; Truong L; Fitchett J; Levin AA
    J Pharm Sci; 2004 Jan; 93(1):48-59. PubMed ID: 14648635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.
    Yu RZ; Gunawan R; Post N; Zanardi T; Hall S; Burkey J; Kim TW; Graham MJ; Prakash TP; Seth PP; Swayze EE; Geary RS; Henry SP; Wang Y
    Nucleic Acid Ther; 2016 Dec; 26(6):372-380. PubMed ID: 27500733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTP Toxicology and Carcinogenesis Studies of Talc (CAS No. 14807-96-6)(Non-Asbestiform) in F344/N Rats and B6C3F1 Mice (Inhalation Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 421():1-287. PubMed ID: 12616290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated Assessment of the Clinical Performance of GalNAc
    Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
    Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice.
    Templin MV; Levin AA; Graham MJ; Aberg PM; Axelsson BI; Butler M; Geary RS; Bennett CF
    Antisense Nucleic Acid Drug Dev; 2000 Oct; 10(5):359-68. PubMed ID: 11079575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys.
    Monteith DK; Geary RS; Leeds JM; Johnston J; Monia BP; Levin AA
    Toxicol Sci; 1998 Dec; 46(2):365-75. PubMed ID: 10048140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicology and carcinogenesis studies of indium phosphide (CAS No. 22398-90-7) in F344/N rats and B6C3F1 mice (inhalation studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2001 Jul; (499):7-340. PubMed ID: 12087422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Repeated Complement Activation Associated with Chronic Treatment of Cynomolgus Monkeys with 2'-O-Methoxyethyl Modified Antisense Oligonucleotide.
    Shen L; Engelhardt JA; Hung G; Yee J; Kikkawa R; Matson J; Tayefeh B; Machemer T; Giclas PC; Henry SP
    Nucleic Acid Ther; 2016 Aug; 26(4):236-49. PubMed ID: 27140858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice.
    Fortin M; D'Anjou H; Higgins ME; Gougeon J; Aubé P; Moktefi K; Mouissi S; Séguin S; Séguin R; Renzi PM; Paquet L; Ferrari N
    Respir Res; 2009 May; 10(1):39. PubMed ID: 19457265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.